ATMI Inc

ATMI — Q2 2012 Earnings Presentation

9 slides from ATMI's earnings presentation, Jul 25, 2012

  1. Slide 1: Q2 2012 Earnings Teleconference

    Q2 2012 Earnings Teleconference July 25, 2012 ¢ Aa |

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained herein that relate to ATMI’s future performance, including, without limitation, statements with respect to ATMI’s anticipated results of operations or level of business for 2012 or any other future period, are forward-looking statements within the safe harb

  3. Slide 3: Q2 2012 Financial Summary

    Q2 2012 Financial Summary Revenue grew 14% Q/Q and 2% Y/Y > SDS Direct transition complete and meeting expectation > LifeSciences grew 19% on strong consumable growth Improved profitability > Gross margins >50% > 16% operating margins Cash provided by operating activities up 79% Long-term growth out

  4. Slide 4: ATMI consolidated results

    ATMI $M (except per share data) Q22012 Q22011 Change Q12012 Change Revenue 105.9 104.0 +2% 92.6 +14% Gross profit 53.5 49.5 +8% 44.2 +21% Gross margin 50.5% 47.5% 47.7% Operating income 16.9 15.4 +10% 6.1 +176% Operating margin 16.0% 14.8% 6.6% Net income 11.4 tal il, 43% 3.9 +195% EPS $0.35 $0.34 $

  5. Slide 5: Diverse revenue mix

    Diverse revenue mix Q2 2012 Revenues by Product Q2 2012 Revenues by Sector mlmplant 26% BLogic 56% ™Cu Materials 45% ™ Memory 25% ™ NOWPak 13% ™ Display 8% mlifeSciences 11% m LifeSciences 11% Other 5% @ ATM!

  6. Slide 6: Microelectronics

    Microelectronics Q22012 Q22011 Change Q12012 Change Revenue 94.6 94.6 +0% 83.5 +13% Gross margin 52% 50% 50% Operating income 30.5 28.3 +8% 21.0 +45% Operating margin 32.2% 29.9% 25.2% > SDS added $5.8M net revenues and drove gross margin improvement > Display down on lower demand and unfavorable mi

  7. Slide 7: SDS Direct financial summary

    SDS Direct financial summary Financial impact per quarter (SM, except EPS) Q42011 —Q12012 Q22012 Revenue Incremental revenue $1.9 $4.5 $7.7 $7 -$8 Inventory repurchase and bum ($8.8) ($7.0) ($1.9) S Net revenue ($6.9) ($2.5) $5.8 $7 - $8 Expense Contract termination $84.6 - = - Incremental operating

  8. Slide 8: LifeSciences

    LifeSciences Q22012 Q22011 Change Q12012 Change Revenue 11.2 9.4 +19% O11, +22% Gross margin 38% 27% 32% Operating (loss) (1.1) (1.9) (2.1) Operating margin (9.9%) (19.9%) (23.3%) > Growth in single-use technology is accelerating > Profitability improving with higher mix of consumables > 20-30% CAGR

  9. Slide 9: Thank you for your interest

    @O ATM! Thank you for your interest. Troy Dewar Director, Investor Relations 203.207.9349 [email protected]

Atmi — Q2 2012 Earnings Presentation on 6ix